CELU — Celularity Inc.
Is CELU overbought or oversold? Here is the current MarketMoodz read.
Celularity Inc. (CELU) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.62. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.62
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Celularity Inc. displays the profile of an early-stage biotech with meaningful upside tied to clinical/partnering catalysts but elevated execution and financing risk. Market conditions show cautious optimism for growth names in the near term, which could support sporadic re-risking into small-cap biotech shares; however, the absence of recent filings and social/research signals raises informational opacity. Convertible-debt and financing trends in the sector increase the likelihood of future dilution. Near-term scenarios include limited upside on discrete positive news or partnership announcements and meaningful downside if financing or clinical setbacks occur.
Key factors
- Early-stage biotech profile with limited public financial disclosures in the supplied data, implying elevated uncertainty around cash runway and operating metrics
- Sector backdrop: risk-on sentiment can support short-term re-risking into growth/biotech names, but rotation toward large-cap pharma may limit sustained capital flows to micro/small-cap biotechs
- Capital markets/dilution pressure theme: convertible-debt and other financing activity in the broader biotech space increases the probability of future equity issuance or dilutive financings
- Clinical and pipeline optionality (typical for cell-therapy/biotech issuers) provides asymmetric upside if near-term development or partnership catalysts emerge
- No recent EDGAR filing comparison or social sentiment data provided, which increases informational opacity and short-term price volatility
- Relative illiquidity and low share price increase sensitivity to single announcements and insider/strategic moves
Risks
- Cash runway and need for dilutive financing absent confirmed non-dilutive funding or partnership — potential for significant share dilution
- Clinical development or regulatory setbacks that materially reduce the value of pipeline assets
- Adverse market rotations away from small-cap biotech into defensive large-cap pharma, reducing investor demand
- Limited transparency in the provided dataset (no EDGAR filing comparison, no social/research signals) increases execution and information risk
- Competition from better-capitalized cell therapy and biopharma companies could limit commercial/partnering opportunities
- High intraday and short-term volatility given low absolute share price and potential low liquidity
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for CELU — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.